section name header

Pronunciation

DOR-a-VIR-een

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: non nucleoside reverse transcriptase inhibitors

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 64% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Primarily metabolized in the liver by the CYP3A enzymes. Primarily excreted in feces (as metabolites), 6% unchanged in urine.

Half-life: 15 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2 hr24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash.

Endo: Graves' disease.

GI: diarrhea, abdominal pain, autoimmune hepatitis, hyperbilirubinemia, lipase, liver enzymes, nausea.

GU: serum creatinine.

MS: creatine kinase, polymyositis.

Neuro: abnormal dreams, dizziness, fatigue, Guillain-Barré syndrome, headache, insomnia, sedation.
Misc: immune reconstitution syndrome.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Pifeltro